tirzepatide off label and Beta Blockers: Safety and Interactions Off-label use of semaglutide and

Tapering Considerations: Gradually reduce GLP-1 dosing while increasing fiber and protein intake Begin nutraceutical support (e.g., berberine, chromium) 24 weeks prior to taper Monitor lean mass and glycemic variability Support appetite signaling with mindful eating and circadian regulation Address gut motility and emotional eating patterns with botanical support Clinical Example: A Case in Practice A 52-year-old female on semaglutide for 6 months presented with nausea, fatigue, and concern about lean mass loss

Prescribers initiating BPC-157 in patients with Child-Pugh A or B hepatic impairment should document: (1) the clinical rationale for peptide therapy, (2) the absence of an FDA-approved alternative for the target condition, (3) baseline hepatic function with planned monitoring intervals, and (4) the patient's informed consent acknowledging the investigational nature of the therapy and the specific evidence limitations in their population

HUBERMAN: I think in large part, that's due to the fact that the anecdata about BPC-157 is just so strong

Weight loss medications, including FDA-approved prescription drugs, are often prescribed to individuals with a high body mass index (BMI) and weight-related health conditions

Naltrexone is approved by the Food and Drug Administration (FDA) to help people stop drinking or cut back on drinking, as well as to reduce alcohol cravings

10.1038/s41580-024-00715-1 94 PengZ.GillissenB.RichterA.SinnbergT.SchlaakM